These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 14528282)

  • 1. Biologic and therapeutic role of HER2 in cancer.
    Ménard S; Pupa SM; Campiglio M; Tagliabue E
    Oncogene; 2003 Sep; 22(42):6570-8. PubMed ID: 14528282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HER2/neu in tumor progression and therapy.
    Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
    Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of HER2 gene overexpression in breast carcinoma.
    Ménard S; Tagliabue E; Campiglio M; Pupa SM
    J Cell Physiol; 2000 Feb; 182(2):150-62. PubMed ID: 10623878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing: a review of detection methodologies and their clinical performance.
    Laudadio J; Quigley DI; Tubbs R; Wolff DJ
    Expert Rev Mol Diagn; 2007 Jan; 7(1):53-64. PubMed ID: 17187484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
    Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer.
    De Maria R; Olivero M; Iussich S; Nakaichi M; Murata T; Biolatti B; Di Renzo MF
    Cancer Res; 2005 Feb; 65(3):907-12. PubMed ID: 15705889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G; Carter WB
    Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.
    Ouyang X; Gulliford T; Huang GC; Harper-Wynne C; Shousha S; Epstein RJ
    Mol Diagn; 2001 Mar; 6(1):17-25. PubMed ID: 11257208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p95HER2 and breast cancer.
    Arribas J; Baselga J; Pedersen K; Parra-Palau JL
    Cancer Res; 2011 Mar; 71(5):1515-9. PubMed ID: 21343397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of HER2 in breast cancer].
    Tóth J; Szentkuti A
    Magy Onkol; 2000 Apr; 44(1):39-51. PubMed ID: 12050766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 fragmentation and breast cancer stratification.
    Arribas J; Parra-Palau JL; Pedersen K
    Clin Cancer Res; 2010 Aug; 16(16):4071-3. PubMed ID: 20682714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas.
    Zohar S; Baldi I; Forni G; Merletti F; Masucci G; Gregori D
    Pharm Stat; 2011; 10(3):218-26. PubMed ID: 20922817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.
    Di Modugno F; Buglioni S; Mottolese M; Del Bello D; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother (1991); 2001 May; 24(3):221-231. PubMed ID: 11395637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.